MLKL and neoplasm: In terms of tumour size control, when MLKL-overexpressing KPC cells were subcutaneously transplanted into C57BL/6 mice, the combination regimen achieved the greatest improvement in tumour size control and survival, surpassing that of GW or CD47 blockade alone (Fig. 9g, h, Supplementary Fig. 12f).